Mirjam Kolev Adela-Cristina Sarbu Burkhard Möller Britta Maurer Florian Kollert Nasser Semmo
10.1016/j.jtauto.2023.100189
J Transl Autoimmun
2023 Jan 14;6:100189.
aih, autoimmune hepatitis alt, alanine aminotransferase ama, anti-mitochondrial antibodies ana, anti-nuclear antibodies ap, alkaline phosphatase aps, anti-phospholipid-antibody syndrome aza, azathioprine autoimmune hepatitis autoimmune liver disease bdn, budesonide belimumab ci, calcineurin inhibitor cya, cyclosporine a inr, international normalized ratio igg, immunoglobulin g igm, immunoglobulin m lc 1, liver cytosol 1 antibodies lkm-1, liver-kidney-microsomal antibodies mmf, mycophenolate mofetil mrcp, magnetic resonance cholangiopancreatography na, not applicable nrh, nodular regenerative hyperplasia pbc, primary biliary cholangitis pdn, prednisolone pla2r, anti-phospholipase 2 receptor antibody psc, primary sclerosing cholangitis primary biliary cholangitis rf, rheumatoid factor sla, soluble liver antigen antibodies sle, systemic lupus erythematosus sma, smooth-muscle cell antibodies ss-a, ss-a (ro) antibodies ss-b, ss-b (la) antibodies sjögren's disease tnfi, tumor necrosis factor inhibitor udca, ursodeoxycholic acid uln, upper limit of normal disease-modifying anti-rheumatic drugs, dmards
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/36718275/
PMC9883290
36718275
Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series
2023